Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection

Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) has received final approval from the USFDA to market Cyanocobalamin Injection in the strengths of 1,000 mcg/mL,10,000 mcg/10 mL (1,000 mcg/mL), and 30,000 mcg/30 mL (1,000 mcg/mL) Multiple-Dose Vials. (US RLD: Cyanocobalamin). Cyanocobalamin injection is used to treat and prevent lack of vitamin B12 that may be caused due to pernicious anemia (lack of a natural substance needed to absorb vitamin B12 from the intestine), certain diseases, infections or medications decrease the amount of vitamin B12 absorbed from food. The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat.

The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Ltd was last trading in BSE at Rs. 364.65 as compared to the previous close of Rs. 363.10. The total number of shares traded during the day was 33542 in over 890 trades.

The stock hit an intraday high of Rs. 369.00 and intraday low of 361.25. The net turnover during the day was Rs. 12275667.00.

Source : Equity Bulls

Keywords

ZydusLifesciences CadilaHealthcare INE010B01027 FinalApproval USFDA CyanocobalaminInjection VitaminB12